MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Interest Income
Income earned on cash, deposits, and investments held by the company.
MediciNova, Inc.NASDAQ: MNOV
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income dips below year-ago levels
Q1 FY2026 interest income of $252.96K fell 24.7% year over year, behind the +21095.8% change in trailing-twelve-month interest income. Sequentially, it fell 99.9% from the prior quarter. Over 3 fiscal years it compounded at +17.2% a year.
Context
- Interest income amounted to 318.3% of revenue in FY2025.
- Interest income increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -24.7% toward the trailing-twelve-month pace of +21095.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 1.3M USD
- Year-over-year change
- -22.0%
- 4-year CAGR
- +73.6%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.3M | -22.0% |
| FY2024 | 2024-12-31 | 1.67M | -8.9% |
| FY2023 | 2023-12-31 | 1.83M | +126.6% |
| FY2022 | 2022-12-31 | 809.67K | +463.7% |
| FY2021 | 2021-12-31 | 143.63K | — |
Interest Income vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's LTM Mar 2026 interest income of $341.13M is the highest of the 11 companies compared; the peer median is $2.24M.
- Its year-over-year change of +21095.8% is the highest of 11, against a peer median of -39.5%.
- Interest income amounts to 57174.4% of revenue for MNOV, versus a peer median of 6.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $341.13M | +21095.8% | +17.2% | 57174.4% | |
| LTM Mar 2026 | $7.18M | -43.4% | +77.0% | 78.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.47M | -43.9% | — | — |
| LTM Mar 2026 | $5.38M | -44.2% | +20.4% | — | |
| LTM Mar 2026 | $5.09M | -41.2% | +14.1% | — | |
| LTM Mar 2026 | $2.57M | +9.7% | +21.1% | 3.9% | |
| LTM Mar 2026 | $1.92M | -34.3% | -19.3% | — | |
| LTM Mar 2026 | $1.84M | -55.1% | +1.0% | — | |
| LTM Mar 2026 | $1.71M | -31.0% | +8.6% | 0.7% | |
| LTM Mar 2026 | $1.62M | -32.2% | -0.0% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $347K | -37.7% | +94.0% | 8.1% |
| Peer median (excluding MNOV) | $2.24M | -39.5% | +14.1% | 6.0% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.04M | 0 | 1M | 0 | 409.66K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 378.61K |
| Gross Profit | 4.04M | 0 | 1M | 0 | 31.05K |
| Gross Margin | 100.0% | — | 100.0% | — | 7.6% |
| Research & Development | 8.1M | 9.14M | 5.66M | 7.2M | 7.15M |
| Selling, General & Admin | 5.72M | 5.48M | 5.24M | 5.48M | 6.16M |
| Operating Expenses | 14.25M | 14.63M | 10.9M | 12.68M | 13.31M |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| EBITDA | (10.11M) | (14.05M) | (8.55M) | (11.02M) | (11.97M) |
| EBITDA Margin | -250.3% | — | -854.8% | — | -2922.4% |
| Operating Income | (10.22M) | (14.63M) | (9.9M) | (12.68M) | (13.28M) |
| Operating Margin | -253.0% | — | -990.0% | — | -3242.5% |
| Interest Income | 143.63K | 809.67K | 1.83M | 1.67M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 84.13K | 562.39K | 1.33M | 1.63M | 1.29M |
| Income Before Tax | (10.13M) | (14.07M) | (8.57M) | (11.04M) | (11.99M) |
| Pre-Tax Margin | -250.9% | — | -856.8% | — | -2927.3% |
| Income Tax Expense | 2.57K | 2.82K | 3.05K | 5.54K | 5.99K |
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Net Margin | -251.0% | — | -857.2% | — | -2928.8% |
| EPS (Basic) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| EPS (Diluted) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| Weighted Avg Shares | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
| Weighted Avg Shares (Diluted) | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.